Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3TR-PARTNER-RA abatacept biomarker study in early rheumatoid arthritis
NL-OMON60829Phase 4Completed
- Sponsor
- Queen Mary University of London
- Start
- Feb 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of abatacept in rheumatoid arthritis (RA), sponsored by Queen Mary University of London. Started Feb 2025; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON60829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60829.